The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Gritsaev S.V.

Rossiĭskiĭ NII gematologii i transfuziologii, Sankt-Peterburg;
K/O "Gematologiia"

Kostroma I.I.

Rossiĭskiĭ NII gematologii i transfuziologii FMBA Rossii, Sankt-Peterburg

Zapreev I.M.

Russian Research Institute of Hematology and Transfusiology, Federal Biomedical Agency of Russia, Moscow, Russia

Shmidt A.V.

Russian Research Institute of Hematology and Transfusiology, Federal Biomedical Agency of Russia, Moscow, Russia

Tiranova S.A.

FGBU "Rossiĭskiĭ NII gematologii i transfuziologii" FMBA, Sankt-Peterburg

Balashova V.A.

Russian Research Institute of Hematology and Transfusiology, Federal Biomedical Agency of Russia, Moscow, Russia

Martynkevich I.S.

Klinicheskiĭ otdel "Gematologiia" Rossiĭskogo nauchno-issledovatel'skogo instituta gematologii i transfuziologii, Sankt-Peterburg

Chubukina Zh.V.

Rossiĭskiĭ NII gematologii i transfuziologii

Semenova N.Yu.

Laboratory of Pathomorphology, Saint Petersburg Research Institute of Phthisiopulmonology

Chechetkin A.V.

Russian Research Institute of Hematology and Transfusiology, Federal Biomedical Agency of Russia, Moscow, Russia

Transformation of secondary myelodysplastic syndrome to atypical chronic myeloid leukemia in a female patient with acute myeloid leukemia

Authors:

Gritsaev S.V., Kostroma I.I., Zapreev I.M., Shmidt A.V., Tiranova S.A., Balashova V.A., Martynkevich I.S., Chubukina Zh.V., Semenova N.Yu., Chechetkin A.V.

More about the authors

Journal: Therapeutic Archive. 2016;88(7): 104‑108

DOI: 10.17116/terarkh2016887104-108

Read: 3439 times

Download PDF (RU)
Contact the author
Table of contents

TRANSFORMATION OF SECONDARY MYELODYSPLASTIC SYNDROME TO ATYPICAL CHRONIC MYELOID LEUKEMIA IN A FEMALE PATIENT WITH ACUTE MYELOID LEUKEMIA
TRANSFORMATION OF SECONDARY MYELODYSPLASTIC SYNDROME TO ATYPICAL CHRONIC MYELOID LEUKEMIA IN A FEMALE PATIENT WITH ACUTE MYELOID LEUKEMIA

To cite this article:

Gritsaev SV, Kostroma II, Zapreev IM, et al. Transformation of secondary myelodysplastic syndrome to atypical chronic myeloid leukemia in a female patient with acute myeloid leukemia. Therapeutic Archive. 2016;88(7):104‑108. (In Russ.)
https://doi.org/10.17116/terarkh2016887104-108

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Secondary myeloid neoplasia may be a complication of intensive cytostatic therapy. The most common types of secondary neoplasias are acute myeloid leukemia and myelodysplastic syndrome. The development of secondary atypical chronic myeloid leukemia (aCML) is an extremely rare phenomenon. The paper describes transformation of secondary myelodysplastic syndrome to aCML 6 months after its diagnosis. The development of aCML was accompanied by additional chromosomal aberration as monosomy of chromosome 17. No mutations in the JAK2, MPL, and CalR genes were detected. It is concluded that the clinical course of secondary myeloid neoplasias is variable.

Keywords:

secondary myelodysplastic syndrome
secondary atypical chronic myeloid leukemia

Authors:

Gritsaev S.V.

Rossiĭskiĭ NII gematologii i transfuziologii, Sankt-Peterburg;
K/O "Gematologiia"

Kostroma I.I.

Rossiĭskiĭ NII gematologii i transfuziologii FMBA Rossii, Sankt-Peterburg

Zapreev I.M.

Russian Research Institute of Hematology and Transfusiology, Federal Biomedical Agency of Russia, Moscow, Russia

Shmidt A.V.

Russian Research Institute of Hematology and Transfusiology, Federal Biomedical Agency of Russia, Moscow, Russia

Tiranova S.A.

FGBU "Rossiĭskiĭ NII gematologii i transfuziologii" FMBA, Sankt-Peterburg

Balashova V.A.

Russian Research Institute of Hematology and Transfusiology, Federal Biomedical Agency of Russia, Moscow, Russia

Martynkevich I.S.

Klinicheskiĭ otdel "Gematologiia" Rossiĭskogo nauchno-issledovatel'skogo instituta gematologii i transfuziologii, Sankt-Peterburg

Chubukina Zh.V.

Rossiĭskiĭ NII gematologii i transfuziologii

Semenova N.Yu.

Laboratory of Pathomorphology, Saint Petersburg Research Institute of Phthisiopulmonology

Chechetkin A.V.

Russian Research Institute of Hematology and Transfusiology, Federal Biomedical Agency of Russia, Moscow, Russia

Close metadata

References:

  1. Savchenko V, Parovichnikova E, Afanas'ev B, Gricaev S, Semochkin S, Bondarenko S, Troitskaia V, Sokolov A, Kuz'mina L, Kliasova G, Baranova O, Lapin V, Konstantinova T, Samoĭlova O, Kaporskaia T, Shatokhin S. National recommendations on the diagnosis and treatment of adult patients with acute myeloid leukemia. Gematologiya i transfuziologiya. 2014;(pril. 2):(In Russ.)
  2. Abdulkadyrov K, Gricaev S, Bessmel'cev S, Martynkevich I, Tiranova S, Blinov M, Stel'mashenko L, Pesterova V. Secondary myelodysplastic syndrome in patients with multiple myeloma. Terapevticheskii arkhiv. 2004;76(7):85-87. (In Russ.)
  3. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292-2302. doi:10.1182/blood-2002-04-1199
  4. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A, Bloomfield CD. The 2008 revision of the World health Organisation (WHO) classification of myeloid neoplasms and acute myeloid leukemia: rationale and important changes. Blood. 2009;114(5):937-951.  doi:10.1182/blood-2009-03-209262 
  5. Wong TN, Ramsingh G, Young AL, Miller CA, Touma W, Welch JS, Lamprecht TL, Shen D, Hundal J, Fulton RS, Heath S, Baty JD, Klco JM, Ding L, Mardis ER, Westervelt P, DiPersio JF, Walter MJ, Graubert TA, Ley TJ, Druley TE, Link DC, Wilson RK. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature. 2014;518(7540):552-555.  doi:10.1038/nature13968 
  6. Ok CY, Patel KP, Garcia-Manero G, Routbort MJ, Peng J, Tang G, Goswami M, Young KH, Singh R, Medeiros LJ, Kantarjian HM, Luthra R, Wang SA. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases. J Hematol Oncol. 2015;8:45.  doi:10.1186/s13045-015-0139-z
  7. Czader M, Orazi A. Therapy-related myeloid neoplasms. Am J Clin Pathol. 2009;132(3):410-425.  doi:10.1309/AJCPD85MCOHHCOMQ
  8. Sill H, Olipitz W, Zebisch A, Schulz E, Wolfler A. Therapy-related myeloid neoplasms: pathobiology and clinical characteristics. Br J Pharmacol. 2011;162(4):792-805.  doi:10.1111/j.1476-5381.2010.01100.x
  9. Hershman D, Neugut AI, Jacobson JS, Wang J, Tsai WY, McBride R, Bennett CL, Grann VR. Acute myeloid leukemia or myelodysplastic syndrome following use of the granulocyte colony-stimulating factor during breast cancer adjuvant chemotherapy. J Natl Cancer Inst. 2007;99(3):196-205.  doi:10.1093/jnci/djk028 
  10. Le Deley MC, Suzan F, Cutuli B, Delaloge S, Shamsaldin A, Linassier C, Clisant S, de Vathaire F, Fenaux P, Hill C. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. J Clin Oncol. 2007;25(3):292-300.  doi:10.1200/jco.2006.05.9048 
  11. Bhatia S. Therapy-related myelodysplasia and acute myeloid leukemia. Semin Oncol. 2013;40(6):666-675.  doi:10.1053/j.seminoncol.2013.09.013
  12. Smith MA, McCaffrey RP, Karp JE. The secondary leukemias: challenges and research directions. J Natl Cancer Inst. 1996;88(7):407-418.  doi:10.1093/jnci/88.7.407 
  13. Alsop S, Sander WG, Elenitoba-Johnson KSJ, Lim MS. Chronic myeloid leukemia as a secondary malignancy after ALK-positive anaplastic large cell lymphoma. Hum Pathol. 2007;38(10):1576-1580. doi:10.1016/j.humpath.2007.05.018 
  14. Singh ZN, Huo D, Anastasi J, Smith SM, Karrison T, Le Beau MM, Larson RA, Vardiman JW. Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant. Am J Clin Pathol. 2007;127(2):197-205.  doi:10.1309/nq3pmv4u8yv39jwj
  15. Satake N, Ishida Y, Otoh Y, Hinohara S, Kobayashi H, Sakashita A, Maseki N, Kaneko Y. Novel MLL-CBP fusion transcript in therapy-related chronic myelomonocytic leukemia with a t(11;16)(q23;p13) chromosome translocation. Genes Chromosomes Cancer. 1997;20(1):60-63.  doi:10.1002/(sici)1098-2264(199709)20:1<60::aid-gcc9>3.3.co;2-o 
  16. Smith SM, Le Beau MM, Huo D, Karrison T, Sobecks RM, Anastasi J, Vardiman JW, Rowley JD, Larson RA. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003;102(1):43-52.  doi:10.1182/blood-2002-11-3343 
  17. Larson RA. Cytogenetics, not just previous therapy, determines the course of therapy-related myeloid neoplasms. J Clin Oncol. 2012;30(19):2300-2302. doi:10.1200/JCO.2011.41.1215
  18. Takeshita A, Naito K, Shinjo K, Sahara N, Matsui H, Ohnishi K, Beppu H, Ohtsubo K, Horii T, Maekawa M, Inaba T, Ohno R. Deletion 6p23 and add(11)(p15) leading to NUP98 translocation in a case of therapy-related atypical chronic myelocytic leukemia transforming to acute myelocytic leukemia. Cancer Genet Cytogenet. 2004;152(1):56-60.  doi:10.1016/j.cancergencyto.2003.10.002 
  19. Wang SA, Hasserjian RP, Fox PS, Rogers HJ, Geyer JT, Chabot-Richards D, Weinzierl E, Hatem J, Jaso J, Kanagal-Shamanna R, Stingo FC, Patel KP, Mehrotra M, Bueso-Ramos C, Young KH, Dinardo CD, Verstovsek S, Tiu RV, Bagg A, Hsi ED, Arber DA, Foucar K, Luthra R, Orazi A. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood. 2014;123(17):2645-2651. doi:10.1182/blood-2014-02-553800
  20. Dohner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, Löwenberg B, Bloomfield CD; European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-474.  doi:10.1182/blood-2009-07-235358
  21. Quintas-Cardama A, Daver N, Kim H, Dinardo C, Jabbour E, Kadia T, Borthakur G, Pierce S, Shan J, Cardenas-Turanzas M, Cortes J, Ravandi F, Wierda W, Estrov Z, Faderl S, Wei Y, Kantarjian H, Garcia-Manero G. A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2014;14(5):401-410.  doi:10.1016/j.clml.2014.03.001
  22. Gricaev S, Martynkevich I, Abdulkadyrov K, Martynenko L, Ivanova M, Aksenova V, Moskalenko M, Zapreeva I. Age-specific characteristics of acute myeloid leukemia karyotypeia. Terapevticheskii arkhiv. 2011;83(1):51-55. (In Russ.)
  23. Gricaev S, Martynkevich I, Abdulkadyrov K, Petrova E, Zapreeva I, Tiranova S, Potihonova N. Complex karyotype is a marker of very poor prognosis in over 70-year-old patients with acute myeloid leukemia and extended types of myelodysplastic syndrome and high comorbidity index. Terapevticheskii arkhiv. 2012;84(7):16-21. (In Russ.)
  24. Bories P, Bertoli S, Berard E, Laurent J, Duchayne E, Sarry A, Delabesse E, Beyne-Rauzy O, Huguet F, Recher C. Intensive chemotherapy, azacitidine, or supportive care in older acute myeloid leukemia patients: an analysis from a regional healthcare network. Am J Hematol. 2014;89(12):244-252.  doi:10.1002/ajh.23848
  25. Fern L, Pallis M, Carter GI, Seedhouse C, Russell N, Byrne J. Clonal haemopoiesis may occur after conventional chemotherapy and is associated with accelerated telomere shortening and defects in the NQO1 pathway; possible mechanisms leading to an increased risk of t-AML/MDS. Br J Haematol. 2004;126(1):63-71.  doi:10.1111/j.1365-2141.2004.05006.x 
  26. Li L, Li M, Sun C, Francisco L, Chakraborty S, Sabado M, McDonald T, Gyorffy J, Chang K, Wang S, Fan W, Li J, Zhao LP, Radich J, Forman S, Bhatia S, Bhatia R. Altered hematopoietic cell gene expression precedes development of therapy-related myelodysplasia/acute myeloid leukemia and identifies patients at risk. Cancer Cell. 2011;20(5):591-605.  doi:10.1016/j.ccr.2011.09.011
  27. Mughal TI, Cross NC, Padron E, Tiu RV, Savona M, Malcovati L, Tibes R, Komrokji RS, Kiladjian JJ, Garcia-Manero G, Orazi A, Mesa R, Maciejewski JP, Fenaux P, Itzykson R, Mufti G, Solary E, List AF. An International MDS/MPN Working Group’s perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms. Haematologica. 2015;100(9):1117-1130. doi:10.3324/haematol.2014.114660
  28. Hu W, Wang X, Yang R, Xie Y, Zhang Z, Lu H, Wu L, Lai M, Yu K. A novel mutation of SETBP1 in atypical chronic myeloid leukemia transformed from acute myelomonocytic leukemia. Clin Case Rep. 2015;3(6):448-452.  doi:10.1002/ccr3.243
  29. Meggendorfer M, Haferlach T, Alpermann T, Jeromin S, Haferlach C, Kern W, Schnittger S. Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia. Haematologica. 2014;99(12):245-246.  doi:10.3324/haematol.2014.113159
  30. Onida F, Ball G, Kantarjian HM, Smith TL, Glassman A, Albitar M, Scappini B, Rios MB, Keating MJ, Beran M. Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia. Cancer. 2002;95(8):1673-1684. doi:10.1002/cncr.10832 
  31. Breccia M, Biondo F, Latagliata R, Carmosino I, Mandelli F, Alimena G. Identification of risk factors in atypical chronic myeloid leukemia. Haematologica. 2006;91(11):1566-1568.
  32. Lim SN, Lee JH, Lee JH, Kim DY, Kim SD, Kang YA, Lee YS, Lee KH. Allogeneic hematopoietic cell transplantation in adult patients with myelodysplastic/myeloproliferative neoplasms. Blood Res. 2013;48:178-184.  doi:10.5045/br.2013.48.3.178
  33. Gricaev S, Martynkevich I, Kostroma I, Aksenova V, Petrova E, Sergeev A, Tiranova S, Potihonova N, Abdulkadyrov K. The lessons from our experience to treat myeloid neoplasms patients with decitabine. Klinicheskaya onkogematologiya. 2012;3:225-231. (In Russ.)
  34. Dao KH, Solti MB, Maxson JE, Winton EF, Press RD, Druker BJ, Tyner JW. Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia. Leuk Res Rep. 2014;3(2):67-69.  doi:10.1016/j.lrr.2014.07.002
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.